PMID- 16360834
OWN - NLM
STAT- MEDLINE
DCOM- 20060510
LR  - 20061115
IS  - 0198-8859 (Print)
IS  - 0198-8859 (Linking)
VI  - 66
IP  - 9
DP  - 2005 Sep
TI  - Direct ex vivo detection of HLA-DR3-restricted cytomegalovirus- and Mycobacterium 
      tuberculosis-specific CD4+ T cells.
PG  - 950-61
AB  - In order to detect epitope-specific CD4+ T cells in mycobacterial or viral 
      infections in the context of human class II major histocompatibility complex 
      protein human leukocyte antigen (HLA)-DR3, two HLA-DR3 tetrameric molecules were 
      successfully produced. One contained an immunodominant HLA-DR3-restricted T-cell 
      epitope derived from the 65-kDa heat-shock protein of Mycobacterium tuberculosis, 
      peptide 1-13. For the other tetramer, we used an HLA-DR3-restricted T-cell 
      epitope derived from cytomegalovirus (CMV) pp65 lower matrix protein, peptide 
      510-522, which induced high levels of interferon (IFN)-gamma-producing CD4+ T 
      cells in three of four HLA-DR3-positive CMV-seropositive individuals up to 0.84% 
      of CD4+ T cells by intracellular cytokine staining. In peripheral blood 
      mononuclear cells from M. tuberculosis-exposed, Mycobacterium bovis bacille 
      Calmette-Guerin (BCG)-vaccinated, or CMV-seropositive individuals, we were able 
      to directly detect with both tetramers epitope-specific T cells up to 0.62% and 
      0.45% of the CD4+ T-cell population reactive to M. tuberculosis and CMV, 
      respectively. After a 6-day culture with peptide p510-522, the frequency of 
      CMV-specific tetramer-binding T cells was expanded up to 9.90% tetramer+ CFSElow 
      (5,6-carboxyfluorescein diacetate succinimidyl ester) cells within the CD4+ 
      T-cell population, further confirming the specificity of the tetrameric 
      molecules. Thus, HLA-DR3/peptide tetrameric molecules can be used to investigate 
      HLA-DR3-restricted antigen-specific CD4+ T cells in clinical disease or after 
      vaccination.
FAU - Bronke, Corine
AU  - Bronke C
AD  - Department of Clinical Viro-Immunology, Sanquin Research and Landsteiner 
      Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam.
FAU - Palmer, Nanette M
AU  - Palmer NM
FAU - Westerlaken, Geertje H A
AU  - Westerlaken GH
FAU - Toebes, Mireille
AU  - Toebes M
FAU - van Schijndel, Gijs M W
AU  - van Schijndel GM
FAU - Purwaha, Veenu
AU  - Purwaha V
FAU - van Meijgaarden, Krista E
AU  - van Meijgaarden KE
FAU - Schumacher, Ton N M
AU  - Schumacher TN
FAU - van Baarle, Debbie
AU  - van Baarle D
FAU - Tesselaar, Kiki
AU  - Tesselaar K
FAU - Geluk, Annemieke
AU  - Geluk A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20050816
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (HLA-DR3 Antigen)
SB  - IM
MH  - Animals
MH  - CD4-Positive T-Lymphocytes/*immunology
MH  - Cell Line, Transformed
MH  - Cytomegalovirus/*immunology
MH  - Cytomegalovirus Infections/*diagnosis
MH  - Epitopes, T-Lymphocyte
MH  - HLA-DR3 Antigen/genetics/metabolism
MH  - Mycobacterium tuberculosis/*immunology
MH  - Transfection
MH  - Tuberculosis/*diagnosis
EDAT- 2005/12/20 09:00
MHDA- 2006/05/11 09:00
CRDT- 2005/12/20 09:00
PHST- 2004/12/20 00:00 [received]
PHST- 2005/06/22 00:00 [revised]
PHST- 2005/06/27 00:00 [accepted]
PHST- 2005/12/20 09:00 [pubmed]
PHST- 2006/05/11 09:00 [medline]
PHST- 2005/12/20 09:00 [entrez]
AID - S0198-8859(05)00126-6 [pii]
AID - 10.1016/j.humimm.2005.06.011 [doi]
PST - ppublish
SO  - Hum Immunol. 2005 Sep;66(9):950-61. doi: 10.1016/j.humimm.2005.06.011. Epub 2005 
      Aug 16.